Recent Updates
Recently added Catalysts

PRX-112

Phase 2

Gaucher Disease | Small molecule | Metabolic |Protalix BioTherapeutics, Inc. (DE)|Last Updated: Sep 27, 2016

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials2
Total Enrollment26
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02107846An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112PHASE2 COMPLETED 10Apr 1, 2014Dec 1, 2015Sep 27, 2016 -
NCT01747980Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease PatientsPHASE1 COMPLETED 16Mar 1, 2013Mar 1, 2014Apr 6, 2014 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
PRX-112DRUG -
Unlock Study Design Details